Armored CLDN18.2 nanobody CAR NK cells
/ iCell Gene Therap
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
March 18, 2026
Preclinical study of armored claudin 18.2 nanobody CAR NK cells targeting gastric cancer
(AACR 2026)
- "Armored CLDN18.2 nanobody CAR NK cells generated via a feeder-independent NK expansion platform showed strong antitumor activity and improved in-vivo performance in CLDN18.2-positive tumor models. CAR NK cells also demonstrated sustained persistence following infusion. Together, these findings support future clinical investigation of our platform in patients with CLDN18.2-positive gastric cancer."
Preclinical • Gastric Cancer • Oncology • Solid Tumor • CLDN18 • IL15
1 to 1
Of
1
Go to page
1